Bleakley Financial Group LLC Increases Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Bleakley Financial Group LLC lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,026 shares of the biopharmaceutical company’s stock after acquiring an additional 404 shares during the quarter. Bleakley Financial Group LLC’s holdings in Alnylam Pharmaceuticals were worth $388,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Harbor Capital Advisors Inc. increased its position in shares of Alnylam Pharmaceuticals by 1.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after acquiring an additional 51 shares during the last quarter. Captrust Financial Advisors boosted its stake in Alnylam Pharmaceuticals by 4.3% in the second quarter. Captrust Financial Advisors now owns 1,285 shares of the biopharmaceutical company’s stock valued at $187,000 after acquiring an additional 53 shares during the period. EP Wealth Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 6.4% in the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 71 shares during the period. CIBC Asset Management Inc boosted its stake in Alnylam Pharmaceuticals by 2.0% in the first quarter. CIBC Asset Management Inc now owns 4,191 shares of the biopharmaceutical company’s stock valued at $840,000 after acquiring an additional 84 shares during the period. Finally, Oppenheimer & Co. Inc. boosted its stake in Alnylam Pharmaceuticals by 2.1% in the third quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company’s stock valued at $800,000 after acquiring an additional 93 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Down 2.4 %

ALNY opened at $148.50 on Monday. The stock has a fifty day moving average of $153.99 and a 200-day moving average of $167.73. The firm has a market capitalization of $18.70 billion, a P/E ratio of -41.71 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12-month low of $143.52 and a 12-month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.68) EPS. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. The Goldman Sachs Group lowered Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $230.00 to $173.00 in a research note on Friday, February 16th. StockNews.com raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $235.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, Chardan Capital decreased their price target on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $216.12.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.